Home>>Signaling Pathways>> Ubiquitination/ Proteasome>> Autophagy>>Cycloheximide


Catalog No.GC17198

Cycloheximide Chemical Structure

Antibiotic,inhibiter of protein synthesis in eukaryotes

Size Price Stock Qty
10mM (in 1mL DMSO)
In stock
In stock
In stock
In stock
In stock

Customer Reviews

Based on customer reviews.

Tel: (626) 353-8530 Email: sales@glpbio.com

Sample solution is provided at 25 µL, 10mM.

Product Citations

Quality Control

Quality Control & SDS

View current batch:


Cell experiment: [1]

Cell lines

SGBS preadipocytes

Preparation method

The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months.

Reaction Conditions

10 μg/ml, 9 hours


Addition of CHX enhanced CD95-induced cleavage of caspase-8 into p43/p41 intermediate and p18 active fragments as well as proteolytic turnover of the proenzyme form of caspase-8 after 1, 3, 6, and 9 h. In addition, CHX increased cleavage of caspase-3 into the active p20/17 fragment at these time points. At later time points (24, 48, and 72 h), a decrease in the p55 pro-form of caspase-8 and the p35 pro-form of caspase-3 was observed. Interestingly, α-APO-1 alone induced caspase-8 and caspase-3 cleavage (3, 6, 9 h) although there is no induction of cell death after 24 h. Involvement of caspase-cleavage was confirmed by the use of the caspase inhibitor Z-VAD.fmk, which reduced CD95- and CHX-induced apoptosis. Apoptosis was rescued by ~50% pointing to a potential role of caspase-independent cell death in SGBS preadipocytes.

Animal experiment: [2]

Animal models

Sprague Dawley rat pups

Dosage form

Intraperitoneal injection, 0.6 mg/kg, 0, 6, 12 or 24 hr


The hypoxia-ischemia model was set up using the rat pups. The hypoxia-ischemia control group (HI) and hypoxia-ischemia were treated with cycloheximide treatment group at 0, 6, 12, 24 and 24 hr after HI (HI_0, 6, 12, 24), respectively. Infarct volume, as measured by morphometric analysis of infarct areas with TTC, was significantly reduced by 92% and 61% when cycloheximide was given 0 or 6 hr after HI respectively, but showed an insignificant trend in infarct reduction if cycloheximide was administered 12 hr after HI compared to the HI control group, and no protective effect was observed when administration was delayed until 24 hr after HI.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.


[1] Fischer-Posovszky P, Keuper M, Nagel S, et al. Downregulation of FLIP by cycloheximide sensitizes human fat cells to CD95-induced apoptosis. Experimental cell research, 2011, 317(15): 2200-2209.

[2] Park W S, Sung D K, Kang S, et al. Therapeutic window for cycloheximide treatment after hypoxic-ischemic brain injury in neonatal rats. Journal of Korean medical science, 2006, 21(3): 490-494.


IC50: N/A

Cycloheximide is an inhibitor of protein biosynthesis in eukaryotic organisms widely used in biomedical research to inhibit protein synthesis in eukaryotic cells studied in vitro. Due to significant toxic side effects, including teratogenesis, DNA damage, and other reproductive effects, cycloheximide is generally used only in in vitro research applications, but not suitable for human use as a therapeutic compound.

In vitro: Cycloheximide blocks the movement of peptidyl-tRNA from acceptor site to the donor site on reticulocyte ribosomes. This translocation reaction is dependent on the transfer enzyme, TF-II, and GTP hydrolysis. Cycloheximide has no effect on the ribosome dependent GTPase activity of TF-II or peptidyl transferase reaction by which peptides on tRNA in the donor ribosomal site are transferred to an amino acid on tRNA in the acceptor site [1].

In vivo: Cycloheximide treatment was effective in attenuating rat brain injury within a 6 hr therapeutic window after hypoxia-ischemia in a newborn rat pup model. These data support the possibility that protein synthesis inhibitors, as well as other anti-apoptotic strategies, may have therapeutic utility in hypoxic-ischemic (HI) events of the developing newborn brain even when treatment is delayed for up to 6 hr after the primary asphyxial insult [2].

Clinical trial: Up to now, cycloheximide is still in the preclinical development stage.

[1] McKeehan W, Hardesty B.  The mechanism of cycloheximide inhibition of protein synthesis in rabbit reticulocytes. Biochem Biophys Res Commun. 1969 Aug 15;36(4):625-30.
[2] Park WS, Sung DK, Kang S, Koo SH, Kim YJ, Lee JH, Chang YS, Lee M.  Therapeutic window for cycloheximide treatment after hypoxic-ischemic brain injury in neonatal rats. J Korean Med Sci. 2006 Jun;21(3):490-4.

Chemical Properties

Cas No. 66-81-9 SDF
Synonyms Naramycin A; Actidione; 3-[2-(3,5-Dimethyl-2-oxocyclohexyl)-2-hydroxyethyl]glutarimide
Chemical Name 4-[(2R)-2-[(1S,3S,5S)-3,5-dimethyl-2-oxocyclohexyl]-2-hydroxyethyl]piperidine-2,6-dione
Canonical SMILES CC1CC(C(=O)C(C1)C(CC2CC(=O)NC(=O)C2)O)C
Formula C15H23NO4 M.Wt 281.4
Solubility ≥ 14.07 mg/mL in DMSO, ≥ 57.6 mg/mL in EtOH, ≥ 14.05 mg/mL in H2O with ultrasonic and warming Storage 4°C, protect from light
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
Shipping Condition Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.

  • Molarity Calculator

  • Dilution Calculator

**When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / CoA (available online).



Review for Cycloheximide

Average Rating: 5 ★★★★★ (Based on Reviews and 36 reference(s) in Google Scholar.)

5 Star
4 Star
3 Star
2 Star
1 Star
Review for Cycloheximide

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.